![Open Access](https://i-scholar.in/lib/pkp/templates/images/icons/fulltextgreen.png)
![Restricted Access](https://i-scholar.in/lib/pkp/templates/images/icons/fulltextred.png)
![Open Access](https://i-scholar.in/lib/pkp/templates/images/icons/fulltextgreen.png)
![Open Access](https://i-scholar.in/lib/pkp/templates/images/icons/fulltext_open_medium.gif)
![Restricted Access](https://i-scholar.in/lib/pkp/templates/images/icons/fulltextred.png)
![Restricted Access](https://i-scholar.in/lib/pkp/templates/images/icons/fulltext_restricted_medium.gif)
Simultaneous Formulation Development, Evaluation and Estimation of Innovative Controlled Release Tablets of Bosentan Formulated with Varied Polymers
Subscribe/Renew Journal
Bosentan is an endothelial receptor antagonist (ERA) indicated for the treatment of Pulmonary arterial hypertension (PAH). The aim of the present study involves the development of controlled release tablets of bosentan. The tablets were prepared to release the drug for a prolong period of time within the GIT, to enhance the bioavailability, to minimize the dosing frequency, and to improve the patient compliance. The tablets were formulated by using various polymers like hydroxyl propyl methyl cellulose, acacia and xanthum. The formulated tablets were evaluated. The drug release from the optimized formulation (F7) was found to be the best after observing the results of dissolution rate and pre & post formulation studies.
Keywords
Controlled Release, Hydroxyl Propyl Methyl Cellulose (HPMC), Bioavailability, Endothelial Receptor Antagonist (ERA), Pulmonary Arterial Hypertension (PAH), Gastro-Intestinal Tract (GIT).
Subscription
Login to verify subscription
User
Font Size
Information
![](https://i-scholar.in/public/site/images/abstractview.png)
Abstract Views: 241
![](https://i-scholar.in/public/site/images/pdfview.png)
PDF Views: 2